–Pharmacies may substitute one biological drug for another if interchangeable.
–Patents on biologicals can be extended by six months if for pediatric use.
–The review process for biosimilar biological drug applications is outlined. After public review and comment, the process may be revised. Application and audit fees are paid by the manufacturers.
–More affordable medicines may be available for children’s hospitals and underserved populations, by forming purchasing pools.